RxCelerate
RxCelerate’s novel model delivers capabilities to discover and develop drugs and provides candidate molecules for development with in vivo and in vitro data. Integrating chemistry, biology, and R&D expertise, the outsourced company provides in vivo pharmacology with cell-based assays and proprietary models across multiple diseases.
It also boasts medicinal chemistry expertise, such as silico screening and the RxNfinity™ dynamic chemical space.
In 2022, the company announced its acquisition of Methuselah Health — a drug discovery specialist in proteomic instability — for an undisclosed sum. The strategic acquisition saw the 2022 launch of ProQuant™— RxCelerate’s proteomics platform to power drug discovery through proprietary improvements in analytics and bioinformatics.
